I can imagine that, just like me, you are worn out with what is happening, how our lives have been turned upside down, the damage to the our economy, the lives lost, concerns about catching the virus, the results of the upcoming elections, and on it goes. And, the worst part is not knowing WHEN or IF things will improve.
I KNOW that’s where faith and trust come it, but honestly, it is still hard!!
The other HARD PART is the contradictory information coming our way and we are left to sort it out. As I understand, the study mentioned below has been ‘peer reviewed’.
Hydroxychloroquine lowers COVID-19 death rate, Henry Ford Health study finds
A Henry Ford Health System study shows the controversial anti-malaria drug hydroxychloroquine helps lower the death rate of COVID-19 patients, the Detroit-based health system said Thursday.
Officials with the Michigan health system said the study found the drug “significantly” decreased the death rate of patients involved in the analysis.
The study analyzed 2,541 patients hospitalized among the system’s six hospitals between March 10 and May 2 and found 13% of those treated with hydroxychloroquine died while 26% of those who did not receive the drug died.
Among all patients in the study, there was an overall in-hospital mortality rate of 18%, and many who died had underlying conditions that put them at greater risk, according to Henry Ford Health System. Globally, the mortality rate for hospitalized patients is between 10% and 30%, and it’s 58% among those in the intensive care unit or on a ventilator.
“As doctors and scientists, we look to the data for insight,” said Steven Kalkanis, CEO of the Henry Ford Medical Group. “And the data here is clear that there was a benefit to using the drug as a treatment for sick, hospitalized patients.”
The study, published in the International Society of Infectious Disease, found patients did not suffer heart-related side effects from the drug. Patients with a median age of 64 were among those analyzed, with 51% men and 56% African American. Roughly 82% of the patients began receiving hydroxychloroquine within 24 hours and 91% within 48 hours, a factor Dr. Marcus Zervos identified as a potential key to the medication’s success.